Clinical trials: Solid Tumor Cancer Treatment With Immunotherapy
Patients With Advanced Solid Tumor, Advanced Solid Tumor With Oncogenic Driver Mutations
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors
This study is aim to evaluate the preliminary efficacy of GH21 combined with previous target therapy or immunotherapy in patients with advanced solid tumors.
- Trial name
- NCT06322095
- Testing
- PD-1, MET inhibitor, ALK inhibitor
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Advanced Solid Tumor
Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor
This is a one arm, open clinical pharmacological exploration study initiated by researchers to evaluate the safety and effectiveness of vesicular stomatitis oncolytic virus injection (Revottack) combined with PD-1 inhibitor in…
- Trial name
- NCT05644509
- Testing
- Oncolytic Virus Injection（Revottack）+PD-1
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Solid Tumor, Cancer
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
The study purpose is to establish the safety and tolerability of IMA201 in patients with solid tumors that express melanoma-associated antigen 4 and/or 8 (MAGEA4/8).
- Conditions
- Solid Tumor, Cancer, Recurrent Solid Tumors, Refractory Solid Tumors
- Trial name
- ACTengine (NCT03247309)
- Testing
- IMA201 Product, IMADetect®
- Where
- 5 sites in United States, Germany
- Volunteers
- 7 people
- Sponsor
- Immatics US, Inc.
Metastatic Solid Cancers, Colorectal Cancer
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses.
- Conditions
- Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT06253520
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Cancer Institute (NCI)